Ofrecen alternativas con diferentes formas de administracin y posibles beneficios adicionales para los pacientes
Something unusual has entered the grammar of U.S
Thus, in principle, widespread GLP-1 use could reduce future healthcare burden from cardiovascular disease and diabetes complications
This fragmentation in the obesity drug race now a projected $100B+ market could be amplifying broader market volatility as investors reprice winner-take-all assumptions
Adding to the mounting reasons why HCPs choose Wegovy , the FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
It can help inhibit the enzyme tyrosinase, which is responsible for melanin production